NCT06016413View on ClinicalTrials.gov

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2026

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Nab paclitaxel

All patients received nab-paclitaxel 260 mg/m2 intravenously on day 1 of each 3-week cycle for 3 cycles.

DRUG

Carboplatin

All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.

DRUG

adelbelimumab

All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.

Trial Locations (1)

510120

Sun Yat-sen Memorial Hospital, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER